NasdaqCM - Delayed Quote USD

Addex Therapeutics Ltd (ADXN)

8.10

+0.09

+(1.12%)

At close: May 9 at 4:00:00 PM EDT

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5

GlobeNewswire 11 days ago

ADXN
+1.12%
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Genev

GlobeNewswire 16 days ago

ADXN
+1.12%
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for

GlobeNewswire 17 days ago

ADXN
+1.12%
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has return all developmen

GlobeNewswire 24 days ago

ADXN
+1.12%
Addex to Present at the 2025 Swiss Equities Baader Conference

Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 08-10, 2025. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advance

GlobeNewswire 3 months ago

ADXN
+1.12%
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and prov

GlobeNewswire 5 months ago

ADXN
+1.12%
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024. The provisional result for the third quarter of 2024

GlobeNewswire 5 months ago

ADXN
+1.12%
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule al

GlobeNewswire 7 months ago

ADXN
+1.12%
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neuroster

GlobeNewswire 7 months ago

ADXN
+1.12%
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel. A pre-recorded video presentation by Mr. Dyer in which he provides a corporate up

GlobeNewswire 8 months ago

ADXN
+1.12%
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior has selected a compound for future development in sub

GlobeNewswire 8 months ago

ADXN
+1.12%
Addex’s Partner Discontinues ADX71149 development in Epilepsy

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy. The partnership betwee

GlobeNewswire 9 months ago

ADXN
+1.12%
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company’s novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London

GlobeNewswire 9 months ago

ADXN
+1.12%
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K. In his presentation, scheduled for 12:00 CEST / 11:00 B

GlobeNewswire 9 months ago

ADXN
+1.12%
Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM). The votes represented 33.79% of the company's outstanding capital. Addex shareholders approved the 2023 annu

GlobeNewswire 10 months ago

ADXN
+1.12%
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. “Building on the recent Neurosterix transaction, w

GlobeNewswire 10 months ago

ADXN
+1.12%
Addex Convenes Annual General Meeting 2024

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Ann

GlobeNewswire 10 months ago

ADXN
+1.12%
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for inves

GlobeNewswire 11 months ago

ADXN
+1.12%

Performance Overview

Return	ADXN	MSCI WORLD (^990100-USD-STRD)
YTD	-1.70%	-0.19%
1-Year	-10.00%	+9.31%
3-Year	-90.58%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Addex Therapeutics Ltd (ADXN)

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Addex to Present at the 2025 Swiss Equities Baader Conference

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Addex’s Partner Discontinues ADX71149 development in Epilepsy

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

Addex Convenes Annual General Meeting 2024

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Performance Overview